Catalysts About SeaStar Medical Holding SeaStar Medical Holding develops and commercializes cell directed extracorporeal therapies to modulate hyperinflammation in critically ill patients. What are the underlying business or industry changes driving this perspective?Read more
Catalysts About SeaStar Medical Holding SeaStar Medical Holding develops and commercializes cell directed extracorporeal therapies targeting hyperinflammatory conditions such as acute kidney injury. What are the underlying business or industry changes driving this perspective?Read more
Catalysts About SeaStar Medical Holding SeaStar Medical develops and commercializes cell directed extracorporeal therapies, including its SCD platform and QUELIMMUNE, to modulate hyperinflammation in critically ill patients. What are the underlying business or industry changes driving this perspective?Read more
SeaStar Medical Holding Corporation, a commercial-stage healthcare company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis. It also develops NEUTRALIZE-AKI, an SCD therapy that is in clinical trials for adult patients with AKI; and other products in various therapeutic areas, including cardiorenal syndrome, hepatorenal syndrome, and myocardial stunning in end-stage renal disease. SeaStar Medical Holding Corporation was founded in 2007 and is headquartered in Denver, Colorado.
